Catch up on coverage from the third day of Revolutionizing Atopic Dermatitis.
De Benedetto shares her expertise on new discoveries in the science of atopic dermatitis at RAD 2023.
In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.
Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.
In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.
In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.
Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.
Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.
Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.